Tudor Investment Corp ET AL Acquires New Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Tudor Investment Corp ET AL bought a new stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 59,896 shares of the company's stock, valued at approximately $576,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its position in shares of MiMedx Group by 265.4% in the third quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company's stock worth $1,757,000 after purchasing an additional 215,995 shares during the period. Barclays PLC grew its position in shares of MiMedx Group by 163.9% in the 3rd quarter. Barclays PLC now owns 262,449 shares of the company's stock worth $1,550,000 after buying an additional 163,005 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of MiMedx Group by 15.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,802,364 shares of the company's stock worth $17,338,000 after buying an additional 238,075 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in MiMedx Group in the 4th quarter worth approximately $887,000. Finally, SG Americas Securities LLC boosted its stake in MiMedx Group by 79.9% in the 4th quarter. SG Americas Securities LLC now owns 83,385 shares of the company's stock worth $802,000 after purchasing an additional 37,031 shares in the last quarter. Institutional investors own 79.15% of the company's stock.

MiMedx Group Stock Performance

MDXG traded down $0.27 during trading on Wednesday, hitting $6.91. The stock had a trading volume of 220,240 shares, compared to its average volume of 693,019. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The firm has a market capitalization of $1.02 billion, a P/E ratio of 12.55 and a beta of 1.85. The company's 50-day moving average price is $7.25 and its 200 day moving average price is $8.15. MiMedx Group, Inc. has a twelve month low of $5.47 and a twelve month high of $10.14.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, meeting the consensus estimate of $0.06. The company had revenue of $88.21 million for the quarter, compared to analyst estimates of $86.32 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. On average, equities research analysts forecast that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

Insider Buying and Selling at MiMedx Group

In other news, CEO Joseph H. Capper acquired 200,000 shares of MiMedx Group stock in a transaction on Friday, May 2nd. The stock was bought at an average cost of $6.34 per share, with a total value of $1,268,000.00. Following the completion of the purchase, the chief executive officer now owns 529,530 shares of the company's stock, valued at $3,357,220.20. This represents a 60.69% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO William Frank Iv Hulse sold 54,596 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44. Following the completion of the sale, the chief accounting officer now directly owns 440,178 shares of the company's stock, valued at $3,473,004.42. This trade represents a 11.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 144,018 shares of company stock worth $1,130,312 over the last 90 days. Insiders own 1.30% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on MDXG shares. Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th. StockNews.com downgraded shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 9th.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.